- Home
- SNDX vs KBDC Comparison
SNDX vs KBDC Comparison
Compare SNDX & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- KBDC
- Stock Information
- Founded
- SNDX 2005
- KBDC 2021
- Country
- SNDX United States
- KBDC United States
- Employees
- SNDX N/A
- KBDC N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- KBDC
- Sector
- SNDX Health Care
- KBDC
- Exchange
- SNDX Nasdaq
- KBDC Nasdaq
- Market Cap
- SNDX 1.1B
- KBDC 1.1B
- IPO Year
- SNDX 2016
- KBDC N/A
- Fundamental
- Price
- SNDX $9.34
- KBDC $16.00
- Analyst Decision
- SNDX Strong Buy
- KBDC Buy
- Analyst Count
- SNDX 11
- KBDC 4
- Target Price
- SNDX $34.00
- KBDC $16.38
- AVG Volume (30 Days)
- SNDX 2.0M
- KBDC 140.1K
- Earning Date
- SNDX 07-31-2025
- KBDC 08-11-2025
- Dividend Yield
- SNDX N/A
- KBDC 11.89%
- EPS Growth
- SNDX N/A
- KBDC N/A
- EPS
- SNDX N/A
- KBDC N/A
- Revenue
- SNDX $43,722,000.00
- KBDC N/A
- Revenue This Year
- SNDX $431.08
- KBDC $193.84
- Revenue Next Year
- SNDX $105.38
- KBDC $12.68
- P/E Ratio
- SNDX N/A
- KBDC N/A
- Revenue Growth
- SNDX N/A
- KBDC N/A
- 52 Week Low
- SNDX $8.58
- KBDC $13.93
- 52 Week High
- SNDX $25.07
- KBDC $17.99
- Technical
- Relative Strength Index (RSI)
- SNDX 51.90
- KBDC N/A
- Support Level
- SNDX $8.59
- KBDC N/A
- Resistance Level
- SNDX $10.01
- KBDC N/A
- Average True Range (ATR)
- SNDX 0.51
- KBDC 0.00
- MACD
- SNDX 0.15
- KBDC 0.00
- Stochastic Oscillator
- SNDX 87.46
- KBDC 0.00
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.